Loading...
Rheumatology Billing Services
Qualigenix provides rheumatology billing services for rheumatology practices and infusion-integrated groups: infusion and drug coding, biologic prior authorization, J-code unit and JW/JZ wastage review, drug payment reconciliation, and denial follow-up, delivered remotely to practices in 48 states. Most rheumatology revenue sits on the drug line, where a lapsed biologic authorization or a wrong unit count can wipe out an infusion’s margin. Qualigenix checks the authorization, drug units and wastage reporting on every infusion before it’s billed.
What Rheumatology Billing Requires?
Rheumatology billing requires three things on every infusion day: an approved authorization for the drug, the right administration codes in the CMS infusion hierarchy, and drug units that match the vial, including the JW or JZ wastage modifier CMS has required on single-dose container drugs since July 1, 2023. The drug line is where most of a rheumatology practice's revenue sits and where most of it is lost. Qualigenix checks all three before the claim goes out. Book a free billing audit: 786-259-0231.
01
Infusion Hierarchy Coding
When several drugs or infusions are given in one visit, CMS rules decide which line is the initial service and which are add-ons, based on the drug type and the start and stop times. Getting the order wrong underpays the visit or triggers a denial.
01
Biologic Prior Authorization
Infliximab, rituximab, tocilizumab, abatacept and other biologics almost always need prior authorization, often with step therapy proving the patient tried a cheaper drug first. Re-authorizations expire on a schedule many practices don't track.
01
J-Codes, Units and Wastage
Each drug's HCPCS code has its own billing unit, such as 10 mg per unit for infliximab (J1745). Units must match the dose given, and any amount discarded from a single-dose vial must be reported with the JW modifier, or JZ when nothing was discarded.
01
Buy-and-Bill Reconciliation
Under buy-and-bill, the practice pays for the drug before the payer pays the practice. Medicare pays most Part B drugs at average sales price plus a percentage, and commercial contracts vary. Underpaid drug lines that go unchecked erode the margin on every infusion.
01
Medical vs Pharmacy Benefit
Some biologics are covered under the medical benefit when infused in the office and under the pharmacy benefit when self-injected. Checking the wrong benefit leads to denials or patient balances the practice can't collect.
01
Disease-Activity Documentation
Payers want disease-activity scores, prior therapies and lab results in the record to support continued biologic use. Infusion notes also need start and stop times to support the administration codes.
01
Drug-Line Denials
The costliest rheumatology denials come from lapsed authorizations, units that don't match the dose, and missing JW or JZ modifiers. Each one can be caught before the claim is sent.
01
Drug Payment and Audit Rules
Part B drug claims are reviewed for wastage reporting and unit accuracy, and same-day joint injections and office visits are checked against National Correct Coding Initiative (NCCI) edits.
How Qualigenix Protects Rheumatology Drug and Visit Revenue
Qualigenix checks the drug line first, because that's where a single error costs the most.
Infusion-Day Coding
Our coders apply the CMS infusion hierarchy to every infusion visit, using documented start and stop times to assign initial, sequential and concurrent codes. Qualigenix holds 98.9% coding accuracy across all specialties it codes.
Biologic Auth Tracking
We request authorizations and re-authorizations for each biologic, track expiration dates and dose limits, and alert your team before an approval lapses.
Unit and JW/JZ Review
Every drug line is checked for the right HCPCS code, units that match the dose given, and the JW or JZ modifier on single-dose container drugs.
Drug Payment Reconciliation
Drug payments are compared to the expected rate for each payer, and underpaid lines are appealed or flagged for contract review.
Benefit Verification
Each biologic is checked against the patient's medical and pharmacy benefits before it's ordered, so the drug is bought under the benefit that will pay for it.
Documentation Checks
We review infusion notes for start and stop times, and biologic records for disease-activity scores and prior therapies, before the claim is sent.
Denials and Appeals
Denials are worked by cause and appealed where the record supports payment. Qualigenix overturns 79% of the denials it works.
Compliance Monitoring
Drug and injection claims are checked against JW/JZ requirements, NCCI edits and payer drug policies before submission.
Claims, Posting, AR and Reporting
Claims go out with an under 24-hour average submission turnaround, drug and visit payments are posted line by line, and unpaid drug claims are worked first. Reports show drug margin by payer and by biologic.
CASE STUDY 01
How a 3-provider podiatry group cleared $214K in aged A/R
THE SITUATION
A 3-provider podiatry group with roughly 60% Medicare payer mix carried $412,000 in A/R, 38% of it past 120 days. Routine foot care claims (11720, 11721, 11055–11057) had stalled on inconsistent Q7/Q8/Q9 modifiers and class-finding documentation, so payers held or partially paid and nobody worked the remainder. Medicare crossover to secondaries was not being posted, and small patient balances were written off.
WHAT QUALIGENIX DID
We ran a full A/R aging segmentation, worked claims by payer and denial reason rather than by date, rebilled the stalled routine-care claims with corrected modifiers, and reactivated secondary and crossover billing.
Key Outcomes & Turnaround
38% to 14%A/R past 120 days
$214,000recovered from aged A/R
90 daysto turn it around
~60%Medicare payer mix
Audited Practice Results
How a solo podiatrist lifted first-pass acceptance to 96%
THE SITUATION
A solo podiatrist coding 320 encounters a month was stuck at 82% first-pass acceptance. Routine foot care went out without the systemic-condition diagnosis pairing and class findings Medicare requires, so it read as non-covered. Wound debridement was coded to the wrong depth (11042 for skin and subcutaneous where the note supported 11043 for muscle and fascia). Same-day E/M with a procedure went out without modifier 25 and got bundled.
WHAT QUALIGENIX DID
We rebuilt the coding workflow: diagnosis-to-CPT pairing rules for at-risk foot care, correct Q-modifier logic, depth-based debridement coding tied to the operative note, and disciplined use of modifiers 25 and 59/XS.
Key Outcomes & Turnaround
82% to 96%first-pass acceptance
+11%per-encounter reimbursement
60 daysto turn it around
320/moencounters coded
Audited Practice Results
How a 2-location podiatry practice cut its denial rate by two-thirds
THE SITUATION
A 2-location podiatry practice sat at a 19% denial rate, mostly Medicare routine-foot-care and nail-debridement rejections. The denials clustered in three buckets: medical-necessity rejections on routine foot care (missing qualifying diagnosis and class findings), frequency-edit denials on nail debridement billed inside the 60-day window, and missing Q modifiers that flagged services as non-covered.
WHAT QUALIGENIX DID
We built a front-end denial-prevention layer, checking eligibility and coverage against payer LCDs before claims went out, plus a structured appeal workflow with documentation templates mapped to each denial reason.
Key Outcomes & Turnaround
19% to 6%denial rate
$68,000recovered on appealed claims
4 monthsto turn it around
2 locationspractice size
Audited Practice Results
Rheumatology Coding Across Visits, Infusions and Procedures
IV Infusions and Hydration (96360, 96365, 96366, 96413, 96415)
Hydration (96360), therapeutic infusions (96365, 96366) and complex biologic infusions such as rituximab (96413, 96415) are coded by drug type and documented infusion time.
COMPLIANCE
Compliance Section
Rheumatology Practices Infusion-Integrated Rheumatology Groups Autoimmune and Inflammatory Disease Centers Hospital-Based Rheumatology Services Multi-Specialty Medical Networks
0%
Audit Pass Rate
<0%
Variance Threshold
Why Rheumatology Practices Choose Qualigenix
Rheumatology practices choose Qualigenix because it reviews every drug line for authorization, units and wastage, where rheumatology dollars are concentrated.
$0M
Medicare rheumatology dollars paid in error
0%
Improper payment rate on Medicare rheumatology claims
0%
Share of errors from missing or insufficient documentation
0%
Share of errors from coding
QUESTIONS BUYERS ASK
Qualigenix prices rheumatology billing after reviewing your visit and infusion volume, payer mix and drug mix. A free billing audit gives you a quote and checks your drug lines for missed revenue. Call 786-259-0231 to start.
Yes. Every single-dose container drug line is checked for units that match the dose and for the JW modifier when drug was discarded, or JZ when none was, as CMS has required since July 1, 2023.
Qualigenix compares each drug payment to the expected rate for that payer and appeals underpaid lines. Reports show your margin by payer and by drug, so you can see which contracts cover acquisition cost.
Yes. Qualigenix works aging infusion and drug claims first, since they carry the most dollars, correcting units and modifiers and appealing where the record supports payment. Most practices start with a free AR review.
We submit authorization requests with the disease-activity scores, prior therapies and labs payers ask for, track each approval's dates and dose limits, and start re-authorizations before the current one expires.
You can when the visit is significant and separately identifiable from the injection, billed with modifier 25 and supported by the note. A visit that only decides to do the injection is included in the procedure.
Qualigenix works in 133 EMR and EHR platforms and bills from the system your practice already uses. We confirm access and workflow during onboarding.
Qualigenix onboards new practices in 6 days on average. Call 786-259-0231 to set a start date.